Professor of Medicine, Ohio State University
Hematology
Dr. Eric H. Kraut, MD
|
|
Give Review
Eric H. Kraut is an expert in the field of Hematology. He attended Temple University School of Medicine. He over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Eric Kraut is a published doctor. He published 99 publications, including: 'The use of topoisomerase I inhibitors in multiple myeloma.'
Publications
- Reduced dose pentostatin for initial management of hairy cell Leukemia patients who have active infection or risk of hemorrhage is safe and effective.
- A phase I trial of flavopiridol in relapsed multiple myeloma.
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast Cancer.
- Myocardial Infarction in Sickle Cell Disease: Use of Translational Imaging to Diagnose an Under-Recognized Problem.
- A phase I study of topotecan and gemcitabine in advanced solid tumors.
- Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein.
- Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell Leukemia.
- A phase II trial of pyrazine diazohydroxide in patients With disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
- A phase II study of topotecan in non-Hodgkin''s lymphoma: an Ohio State University phase II research consortium study.
- A phase II study of CI-980 in previously untreated extensive small cell lung Cancer: an Ohio State University phase II research consortium study.
- Phase II study of topotecan and cyclophosphamide in patients With relapsed and refractory multiple myeloma.
- Cancer- and treatment-related anemia.
- A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic coloRectal carcinoma (MCRC).
- Myocardial ischemia and right ventricular dysfunction in adult patients with sickle Cell disease.
- An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic Thrombocytopenic purpura.
- Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed Acute leukemia.
- Phase II study of dolastatin-10 as first-line treatment for advanced coloRectal cancer.
- Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin With paclitaxel in the rat.
- Clinical manifestations and infectious complications of hairy-Cell leukaemia.
- Pentostatin in the treatment of hairy-cell Leukemia.
- Review: isolated skeletal involvement in hairy cell Leukemia.
- A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients With solid tumors.
- Cancer- and chemotherapy-induced anemia.
- Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients With idiopathic thrombotic thrombocytopenic purpura.
- Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with Cancer.
- Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in Cancer patients.
- A phase II investigation of pentostatin in metastatic malignant Melanoma.
- Analysis of topoisomerase I/DNA complexes in patients administered topotecan.
- Phase II study of CI-958 in patients with hormone refractory prostate Carcinoma.
- A comprehensive phase I and II clinical investigation of fludarabine phosphate.
- Phase II trial of temsirolimus in patients With relapsed or refractory multiple myeloma.
- Capped-dose mitomycin C: a pooled safety Analysis from three prospective clinical trials.
- Phase I trial of homoharringtonine administered by prolonged continuous infusion.
- Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
- Pulmonary embolism as a result of Hickman catheter-related Thrombosis.
- A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung Cancer.
- Infectious complications in hairy cell Leukemia.
- Treatment of Anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only.
- Use of cardiopulmonary bypass to salvage patients With multiple-chamber heart wounds.
- Severe neutropenia caused by recommended prophylactic doses of rifabutin.
- A spontaneous factor V inhibitor With unexpected laboratory features.
- A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined With Weekly Cisplatin and Irinotecan in Patients With Advanced Solid Tumors.
- Bleeding and bruising: a diagnostic work-up.
- Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced Carcinoma of the esophagus.
- The use of topoisomerase I inhibitors in multiple myeloma.
- A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory Acute myeloid leukemia Southwest Onco...
- A phase II study of 9-aminocamptothecin in patients with refractory breast Cancer.
- A phase I study of induction chemotherapy for older patients with newly diagnosed Acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC...
- Phase II trials of pentostatin (Nipent) in hairy cell Leukemia.
- NCCN Practice Guidelines for Acute Myelogenous Leukemia.
- Phase II study of pyrazoloacridine in metastatic renal Cell carcinoma.
- Phase II trial of topotecan in malignant Melanoma.
- Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.
- Myocardial ischemia in a patient with Chronic refractory idiopathic thrombocytopenic purpura.
- Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.
- Glucose metabolism of hairy Cells.
- Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
- Fludarabine phosphate in refractory hairy cell Leukemia.
- Phase II study of pibenzimol in pancreatic Cancer. A Southwest Oncology Group study.
- Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study.
- Combined effects of interferon and 2'-deoxycoformycin on 2',5'-oligoadenylate synthetase and adenosine deaminase in hairy cell and chronic lymphocytic Leukemia cells.
- Immunosuppressive effects of pentostatin.
- Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response With deoxycytidine kinase ac...
- Pentostatin in the treatment of advanced hairy cell Leukemia.
- Effects of treatment with cobra venom factor on experimentally induced feline Leukemia.
- Effects of cobra venom factor treatment on latent feline Leukemia virus infection.
- Low-dose deoxycoformycin in lymphoid malignancy.
- Low-dose deoxycoformycin in the treatment of hairy cell Leukemia.
- Treatment of hairy cell Leukemia: the Ohio State University experience with deoxycoformycin.
- Phase II study of mitoguazone in pancreatic Cancer: a Southwest Oncology Group Study.
- Detection of circulating immune complexes by a Clq/protein A-ELISA during the preneoplastic stages of feline Leukemia virus infection.
- Glucose: a role as a free radical scavenger in biological systems.
- The effect of oxidant injury on the lymphocyte membrane and functions.
- Phase I trial of teroxirone.
- Complement depletion accelerates the clearance of Immune complexes from the circulation of primates.
- The role of reactive oxygen species in thromboxane b2 generation by polymorphonuclear leukocytes.
- Feline complement dependent binding in the Raji Cell assay is insufficient for the quantitation of immune complexes.
- A role for sulfhydryl groups in granulocyte aggregation.
- Activation of the alternative complement pathway in ascitic fluid during spontaneous bacterial peritonitis.
- Alternative pathway of complement in multiple myeloma.
- Evaluation of the role of oxygen radicals in polymorphonuclear leukocyte aggregation.
- Absence of prolonged benefit of initial leukapheresis therapy for hairy cell Leukemia.
- Gallium nitrate in advanced soft tissue and bone sarcomas: a Southwest Oncology Group Study.
- In vitro effects of ascorbate on white Cell metabolism and the chemiluminescence response.
- Cross-resistance to purine analogs in hairy cell Leukemia.
- Phase II evaluation of merbarone in renal Cell carcinoma.
- Long-term follow-up of patients with hairy cell Leukemia after treatment with 2'-deoxycoformycin.
- Phase II trial of merbarone in pancreatic Carcinoma. A Southwest Oncology Group study.
- Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients With advanced solid tumors.
- Evaluation of merbarone (NSC 336628) in disseminated malignant Melanoma. A Southwest Oncology Group study.
- Surgical interventions in a cohort of patients With haemophilia A and inhibitors: an experiential retrospective chart review.
- Phase II clinical trial of arsenic trioxide With liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.
- Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial Analysis of ADAMTS13 activity.
- Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic Thrombocytopenic purpura.
- Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast Cancer.
- Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with Cancer.
- Flavopiridol, fludarabine, and rituximab in mantle Cell lymphoma and indolent B-Cell lymphoproliferative disorders.
- Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous Cell carcinoma of the head and neck (SSCHN).
Schools
Temple University School Of Medicine
University Of Pittsburgh
Ohio State University Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Medical Mutual of Ohio POS
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
University of Pittsburgh Medical Center -
Temple University School of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1780621433 | |
| NPPES Provider LastName | KRAUT | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1012.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 232.0 | |
| Percent Opioid Claims | 22.92 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1780621433 |
| Last Name Of The Provider | KRAUT |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
Dr. Peter J. Kourlas, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. J Paul Monk III, MD |
|
|
Dr. Tarek A. Chidiac, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark H. Knapp, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kristie A. Blum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James S. Blachly, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rebecca J. Klisovic, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David E. Symer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Taral Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph Markowitz, MD |